Participated · Equity · May 2026

NanoStruct has developed a platform that combines nanostructured optical sensor chips with biotechnology and machine learning to detect harmful bacteria in food in a few hours rather than several days. The company positions its system as enabling same-day results, reducing recalls and food waste while improving food safety. NanoStruct is targeting the food-analysis market first and plans pilot projects with food producers and testing laboratories as part of its commercialization. Management, led by CEO Dr. Henriette Maaß, intends to build a structured sales organization to enter its initial target market. The company also sees potential applications of its technology in veterinary and human diagnostics and in bacterial monitoring for sensitive production environments. Financially, the company has secured €2.6 million in initial financing from HTGF, Bayern Kapital and AUXXO to support these next steps.

Led · Seed · May 2026

Founded by Dr Henriette Maaß, Enno Schatz and Kai Leibfried, NanoStruct develops nanostructured sensor chips that combine optical measurement, nanotechnology, biotechnology and machine learning to shorten pathogen detection from days to hours. Its platform aims to provide same-day results for microbial analysis, reducing recalls and food waste while improving food safety. The company highlights potential applicability beyond food into veterinary and human diagnostics and bacterial monitoring in sensitive production environments. NanoStruct has received previous grants from the German Federal Ministry for Economic Affairs and Energy and the European Union to advance its technology. With the newly raised €2.6 million Seed round, the company intends to move toward commercial deployment and scale in the food market. No revenue, user, or valuation figures were disclosed in the article.

Participated · Seed · Apr 2026

BioOrbit develops compact, modular autonomous manufacturing units called BOX to perform crystallisation of biological drugs in microgravity at industry-relevant scale. The company positions BOX as a microwave-sized payload that moves crystallisation from one-off experiments to repeatable manufacturing pathways not achievable on Earth. BioOrbit says its technology enables better-performing biologics and is engaging with the NHS and the UK Space Agency while working on regulatory pathways with the MHRA, Regulatory Innovation Office and CAA. The company was founded and funded by Dr. Katie King and co-founder oncology researcher Dr. Leonor Teles and has appointed senior pharma-and-space executives to its leadership team. BioOrbit has participated in accelerators including Airbus Accelerator, Seraphim Space Accelerator, ESA BSGN Life Sciences, ESA BIC UK and the UK Space Agency LEO Accelerator. The articles do not disclose current revenue or user metrics.

Participated · Seed · Mar 2026

Delta Labs was founded from research backgrounds to create a methodology for AI-based customer simulation that combines market research, quantitative modelling, and human-technology interaction. Six months prior to the announcement the company launched Elaiia, a self-service platform that lets teams simulate expected customer responses across product, pricing, messaging, and strategy using calibrated customer segments grounded in real and company-specific data. The team validated the approach while bootstrapped and secured early customers who used the high-precision methodology. With the €4.4M seed round, Delta Labs plans to expand its team to accelerate product and go-to-market efforts. The company framed the raise as the next step after building confidence in its approach and early traction.

Participated · Seed · Feb 2026

Stanhope AI is developing a brain-inspired system called “Active Inference,” which lets machines learn and adapt on the fly rather than depending on large, static datasets like those used by current LLMs. This adaptive capability targets mission-critical applications across autonomous systems, defence technology, industrial automation, and embedded devices where efficiency and reliability are paramount. The company is led by CEO Professor Rosalyn Moran alongside Professor Karl Friston, both noted researchers in computational neuroscience. With its technology, Stanhope AI aims to bridge the gap between biological cognition and machine learning, offering more efficient and resilient AI solutions. The startup plans to use newly secured capital to accelerate product development and scale operations. To date, its external financing totals $8 million, and no additional operating metrics such as revenue or user figures have been disclosed.